CORRIGENDUM

DOI: 10.3892/ol.2017.6082

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis

KARIN HOLMSTEN, LINE DOHN, NIELS VIGGO JENSEN, CARL-HENRIK SHAH, FREDRIK JÄDERLING, HELLE PAPPOT, and ANDERS ULLÉN

Oncol Lett 12: 1293-1300, 2016; DOI: 110.3892/ol.2016.4775

Following the publication of this article, an interested reader drew to our attention that, on p. 1,298, the two curves in Fig. 2A and B show identical data. The Kaplan-Meier curves in Fig. 2, as published, both show the data for the median overall survival (mOS) curve, and not the mOS and median progression-free survival (mPFS) curves. Fig. 2A was intended to have shown the Kaplan-Meier curve for mPFS, and Fig. 2B the curve for mOS.

A corrected version of Fig. 2, containing the correct data for mOS and mPFS, is shown below. This error did not affect the results or the conclusions reported in this study. We sincerely apologize for this mistake, and thank the reader of our article who drew this matter to our attention. Furthermore, we regret any inconvenience this mistake has caused.




Figure 2. Survival data for patients with metastatic urothelial carcinoma treated with vinflunine as second-line chemotherapy, illustrated by Kaplan-Meier curves. (A) mPFS of 2.8 months (range, 0.5-34.3 months) and (B) mOS of 6.3 months (range, 0.3-39.7 months). mPFS, median progression-free survival; mOS, median overall survival.